|
Jun 26
|
Biomea Fusion Stock Is Trading Higher Today - Here's Why
|
|
Jun 24
|
Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort ...
|
|
Jun 20
|
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023
|
|
Apr 13
|
Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting
|
|
Apr 13
|
Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
|
|
Mar 29
|
Biomea Fusion Announces Proposed Public Offering of Common Stock
|
|
Mar 28
|
Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
|
|
Mar 28
|
Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28
|
|
Mar 23
|
Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET
|